Parathyroid Hormone (PTH) Interpretation
Intact PTH (iPTH) reference range is 15–65 pg/mL (1.6–6.9 pmol/L); interpreted alongside calcium levels, it differentiates parathyroid axis disorders including hyperparathyroidism, hypoparathyroidism, and pseudohypoparathyroidism.
From a thyroid and parathyroid surgery perspective, Parathyroid Hormone (PTH) Interpretation connects the patient's description with objective findings. Intact PTH (iPTH) reference range is 15–65 pg/mL (1.6–6.9 pmol/L); interpreted alongside calcium levels, it differentiates parathyroid axis disorders including hyperparathyroidism, hypoparathyroidism, and pseudohypoparathyroidism. Daily impact, safety signals and response to earlier care must be considered before the term becomes clinically useful. the clinical point assessment interprets neck examination, the dictionary entry nodule behavior, this topic hormone balance, this term vocal fold mobility and the finding family history together. This dictionary entry is patient education that keeps final decisions tied to examination and current reports. The first clinical frame for this entry is to separate functional impact from safety concerns: PTH-Ca interpretation matrix: (1) Ca↑ + PTH↑ or inappropriately normal: primary hyperparathyroidism. This distinction prevents rushed treatment decisions.
Evaluation of the clinical point is less about naming the complaint and more about separating risk from functional effect. the dictionary entry infection clues, this entry trauma history, allergy-reflux pattern, smoking exposure, occupational load and previous surgery can change the pathway. the clinical point review may combine ultrasound findings, the dictionary entry laboratory results, this topic fine-needle biopsy and this term laryngoscopic vocal fold assessment when useful. the finding decisions weigh nodule size, this entry ultrasound pattern, the clinical point lymph-node appearance, the dictionary entry prior biopsy result and this topic risk profile separately. Assessment of the clinical point looks for consistency between history and examination: Measurement considerations: 3rd-generation iPTH assays measure 1-84 PTH (bioactive) and are more reliable than 2nd-generation 'sandwich' assays. If findings do not match, staged reassessment or a second opinion may be clearer than moving directly to a procedure. Tests are meaningful only when they add real value to the clinical plan.
Planning for the dictionary entry compares expected benefit, procedural burden and follow-up needs in the same frame. If patient goals and objective findings do not match, the this topic decision is revisited. this term planning discusses observation, the finding medical adjustment, this entry lobectomy-total thyroidectomy, the clinical point parathyroid strategy or the dictionary entry neck dissection by findings. The goal in this topic is not to choose the most aggressive option, but to find the right step between safe observation and effective intervention. The selected pathway should fit safe monitoring and realistic outcome expectations.
this term follow-up rereads the original goal, current complaint and examination finding in one file. the dictionary entry follow-up reviews calcium balance, this topic voice quality, this term wound healing, the finding pathology results and this entry hormone replacement together. When the clinical point is explained, patient goals, medical necessity and realistic expectations meet on the same ground. Review timing changes when the the dictionary entry risk profile falls or rises.
Preparation for this topic records the most disturbing symptom, pace of change, daily-life effect and prior treatments separately; these notes make diagnostic questions easier to see.
Before the visit symptom onset keeps current symptoms readable.
In the patient file symptom onset keeps current symptoms readable.
Laboratory Assessment
Core panel: serum calcium (total + ionised), phosphorus, iPTH, 25-OH vitamin D, 24h urine calcium + phosphorus + creatinine. Magnesium deficiency impairs PTH secretion; Mg must be measured in every hypocalcaemia workup. PTHrP: measured when malignancy is suspected; elevated PTHrP + suppressed PTH suggests humoral hypercalcaemia of malignancy (HHM). Vitamin D: 25-OH D <20 ng/mL indicates deficiency and can mimic secondary HPT.
Treatment Based on Results
Primary HPT (Ca↑+PTH↑): parathyroidectomy (when surgical criteria met). Secondary HPT (chronic kidney disease): vitamin D analogues (calcitriol, paricalcitol) + phosphorus restriction + calcimimetics (cinacalcet). Vitamin D deficiency: cholecalciferol 2000–4000 IU/day or 50,000 IU/week. Hypoparathyroidism: active vitamin D (calcitriol) + calcium; recombinant PTH in selected cases. Acute hypercalcaemia (Ca >12 mg/dL): IV hydration + furosemide + calcitonin + bisphosphonate.
When to Seek Care
Endocrinology consultation is indicated for serum calcium >11 mg/dL or <7.5 mg/dL, muscle cramps, tetany, kidney stones, or bone fractures. Hypercalcaemic crisis (Ca >14 mg/dL with confusion) requires emergency department presentation.
Frequently asked questions
What is Parathyroid Hormone (PTH) Interpretation?
When is Parathyroid Hormone (PTH) Interpretation clinically important?
When is ENT assessment relevant for Parathyroid Hormone (PTH) Interpretation?
What information helps assessment of Parathyroid Hormone (PTH) Interpretation?
Learn more about this procedure
Detailed guide from Prof. Dr. Özdoğan's clinic
Related terms
References
This glossary entry is for informational purposes only and does not constitute medical advice. Consult a qualified specialist for diagnosis and treatment.